Hypoparathyroidism Pipeline Analysis 2018: 5 Drugs Currently in Different Phases of Development from EnteraBio, Amorphical, Ascendis Pharma, Chugai Pharma and Pharis Pharma - ResearchAndMarkets.com

DUBLIN--()--The "Hypoparathyroidism Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Hypoparathyroidism Pipeline Analysis report covers 5 drugs currently in different phases of development

The report provides Hypoparathyroidism treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.

Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are EnteraBio Ltd., Amorphical Ltd., Ascendis Pharma, Chugai Pharmaceutical Co., Ltd. and Pharis Pharmaceuticals.

Key Topics Covered:

1. Introduction

2. Disease Overview

3. Executive Summary

4. Market Dynamics

5. Pipeline Analysis/Outlook

6. Company Profiling

  • EnteraBio Ltd.
  • Amorphical Ltd.
  • Ascendis Pharma
  • Chugai Pharmaceutical Co., Ltd.
  • Pharis Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/dsjdgc/hypoparathyroidism?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Endocrine and Metabolic Disorders Drugs